Ketorolac Dosing for Acute Pain in Adults
For adults without renal impairment experiencing acute pain, administer ketorolac 15-30 mg IV every 6 hours, with a maximum daily dose of 120 mg and a maximum treatment duration of 5 days. 1
Standard Dosing Regimens
Single-Dose Administration
- IV route: 30 mg as a single dose for patients <65 years 1
- IM route: 60 mg as a single dose for patients <65 years 1
- IV bolus must be given over at least 15 seconds 1
Multiple-Dose Administration (Preferred for Ongoing Pain)
- Standard dose: 30 mg IV or IM every 6 hours 1
- Maximum daily dose: 120 mg 1
- Maximum treatment duration: 5 days total (combined IV/IM and oral) 1
The analgesic effect begins within 30 minutes, peaks at 1-2 hours, and lasts 4-6 hours 1.
Evidence-Based Dose Optimization
Recent high-quality research demonstrates that lower doses of ketorolac provide equivalent analgesia to higher doses. A 2023 systematic review found that 15-20 mg doses are probably as effective as 30 mg doses for acute pain relief (mean difference 0.05 mm on 100 mm VAS, 95% CI -4.91 to +5.01 mm) 2. Similarly, a 2017 randomized trial of 240 ED patients showed no difference in pain reduction between 10 mg, 15 mg, and 30 mg IV doses at 30 minutes 3.
Clinical implication: Consider using 15 mg IV every 6 hours (maximum 60 mg/day) as an equally effective alternative with potentially fewer adverse effects, particularly in patients at moderate risk for complications.
Special Populations Requiring Dose Reduction
Mandatory Lower Dosing (15 mg IV or 30 mg IM every 6 hours, maximum 60 mg/day):
- Age ≥65 years 1
- Body weight <50 kg (110 lbs) 1
- Renal impairment (any degree) 1
- Moderate hepatic impairment 4
Absolute Contraindications:
- Severe renal impairment (CrCl <30 mL/min) 4
- Severe hepatic impairment (Child-Pugh >9) 4
- Active peptic ulcer disease or GI bleeding 5
- Aspirin/NSAID-induced asthma 6
- Pregnancy 6
- Concurrent anticoagulation (warfarin, heparin) increases bleeding risk 5
Critical Safety Considerations
Renal Toxicity
High-risk patients include those aged >60 years, with compromised fluid status, concurrent nephrotoxic drugs, or pre-existing CKD 5.
- A 2026 study of 7,211 THA patients found ketorolac did not increase AKI risk in patients without CKD, but CKD was an independent risk factor for AKI (OR 4.1) 7
- A 2025 propensity-matched study showed ketorolac in patients with CKD increased AKI incidence (12.7% vs 2.0%, P=0.041) 8
- Correct hypovolemia before administering ketorolac 1
- Monitor: Baseline and periodic BUN, creatinine, blood pressure 5
- Discontinue if: BUN or creatinine doubles, or hypertension develops/worsens 5
GI and Cardiovascular Toxicity
High-risk patients: Age >60 years, history of peptic ulcer disease, significant alcohol use (≥2 drinks/day), cardiovascular disease 5
Bleeding Risk
Ketorolac inhibits platelet aggregation. Use with extreme caution in patients with thrombocytopenia, bleeding disorders, or those on anticoagulants 5. However, a randomized trial in pediatric cardiac surgery showed no increased bleeding risk 9.
Practical Clinical Algorithm
Verify eligibility: Exclude contraindications (severe renal/hepatic impairment, active GI bleeding, pregnancy, NSAID allergy)
Assess risk factors:
- Age ≥65, weight <50 kg, or any renal impairment → Use 15 mg IV q6h (max 60 mg/day)
- Age <65, weight ≥50 kg, normal renal function → Use 15-30 mg IV q6h (max 120 mg/day)
Correct hypovolemia before first dose
Administer: IV bolus over ≥15 seconds 1
Monitor: Pain scores at 30 minutes; consider rescue analgesia (low-dose opioid) if inadequate relief 1
Transition: Switch to alternative analgesics as soon as possible; never exceed 5 days total ketorolac therapy 1
Comparative Efficacy
Ketorolac demonstrates equivalent analgesic efficacy to opioids for acute pain. A 2000 trial showed single-dose 30 mg IV ketorolac provided equivalent pain relief to titrated IV meperidine for renal colic (64% vs 72% achieving mild/no pain at 60 minutes, P=0.002 for equivalence) 10. A 2025 systematic review confirmed ketorolac is a valuable opioid alternative in ED settings 11.
For breakthrough pain, do not increase ketorolac dose or frequency—instead, supplement with low-dose opioids as needed 1.